Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae

Respiratory Medicine

Volumn 99, Issue 6, 2005, Pages 663-669

  Cazzola, Mario ^a   Salzillo, Antonello ^a   De Giglio, Carlo ^a   Piccolo, Amedeo ^a   Califano, Clara ^a   Noschese, Paolo ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

23 valent pneumococcal capsular polysaccharide vaccine; Acute exacerbation; Azithromycin; Chronic obstructive pulmonary disease

Indexed keywords

AZITHROMYCIN; FLUTICASONE PROPIONATE PLUS SALMETEROL; PNEUMOCOCCUS VACCINE; PREDNISOLONE;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RELAPSE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; FEMALE; HAEMOPHILUS; HUMANS; KLEBSIELLA; MALE; MIDDLE AGED; MORAXELLA (BRANHAMELLA) CATARRHALIS; PNEUMOCOCCAL VACCINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 18244376117     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2004.11.007     Document Type: Article

References (40)

1. G. Schito E. Debbia A. Marchese The evolving threat of antibiotic resistance in Europe: New data from the Alexander Project J Antimicrob Chemother 46 Suppl. T1 2000 3-9
2. S. Moreno M.E. Garcia-Leoni E. Cercenado M.D. Diaz J.C. Bernaldo de Quiros E. Bouza Infections caused by erythromycin-resistant Streptococcus pneumoniae: Incidence, risk factors, and response to therapy in a prospective study Clin Infect Dis 20 1995 1195-1200
3. C. Fogarty R. Goldschmidt K. Bush Bacteremic pneumonia due to multidrug-resistant pneumococci in three patients treated unsuccessfully with azithromycin and successfully with levofloxacin Clin Infect Dis 31 2000 613-615
4. M.A. Kelley D.J. Weber P. Gilligan M.S. Cohen Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin Clin Infect Dis 31 2000 1008-1011
5. G.W. Waterer R.G. Wunderink C.B. Jones Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy Chest 118 2000 1839-1840
6. D.M. Musher M.E. Dowell V.D. Shortridge R.K. Flamm J.H. Jorgensen P. Le Magueres K.L. Krause Emergence of macrolide resistance during treatment of pneumococcal pneumonia New Engl J Med 346 2002 630-631
7. J.R. Lonks J. Garau L. Gomez M. Xercavins A. Ochoa de Echaguen I.F. Gareen P.T. Reiss A.A. Medeiros Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae Clin Infect Dis 35 2002 556-564
8. A.W. McCormick C.G. Whitney M.M. Farley R. Lynfield L.H. Harrison N.M. Bennett W. Schaffner A. Reingold J. Hadler P. Cieslak M.H. Samore M. Lipsitch Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States Nat Med 9 2003 424-430
9. P. Huovinen O. Cars Control of antimicrobial resistance: Time for action BMJ 317 1998 613-614
10. C. García-Rey L. Aguilar F. Baquero on behalf of the Spanish Surveillance Group for Respiratory Pathogens. Influence of different factors on the ciprofloxacin resistance prevalence of Streptococcus pneumoniae in Spain Antimicrob Agents Chemother 44 2000 3481-3482
11. P. Ball Epidemiology and treatment of chronic bronchitis and its exacerbations Chest 108 Suppl. 1995 43-52
12. R. Guthrie Community-acquired lower respiratory tract infections: etiology and treatment Chest 120 2001 2021-2034
13. C.J. Destache N. Dewan W.J. O'Donohue J.C. Campbell V.A. Angelillo Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis J Antimicrob Chemother 43 Suppl A 1999 107-113
14. M. Cazzola Infektionen der tiefen Atemwege in der Allgemeinpraxis Infection 3 Suppl. 15 1987 S113-9
15. B.R. Celli W. MacNee ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper Eur Respir J 23 2004 932-946
16. J.C. Butler R.F. Breiman J.F. Campbell H.B. Lipman C.V. Broome R.R. Facklam Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations JAMA 270 1993 1826-1831
17. S. Sethi N. Evans B.J. Grant T.F. Murphy New strains of bacteria and exacerbations of chronic obstructive pulmonary disease N Engl J Med 347 2002 465-471
18. D. Bogaert P. van der Valk R. Ramdin M. Sluijter E. Monninkhof R. Hendrix R. de Groot P.W. Hermans Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease Infect Immun 72 2004 818-823
19. J.I. Harwell R.B. Brown The drug-resistant pneumococcus: Clinical relevance, therapy, and prevention Chest 117 2000 530-541
20. P.V. Pepper D.K. Owens Cost-effectiveness of the pneumococcal vaccine in healthy younger adults Med Decision Making 22 Suppl. 5 2002 S45-57
21. K.L. Nichol L. Baken J. Wuorenma A. Nelson The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease Arch Intern Med 159 1999 2437-2442
22. D.S. Fedson D.M. Musher Pneumococcal vaccine In: S.A. Plotkin E.A. Mortimer editors. Vaccines 1994 Saunders London 517-564
23. J.A. Leech A. Gervais F.L. Ruben Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease Can Med Assoc J 136 1987 361-365
24. A.L. Davis C.P. Aranda G. Schiffman L.C. Christianson Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study Chest 92 1987 204-212
25. M. Lipsitch Bacterial vaccines and serotype replacement lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae Emerg Infect Dis 5 1999 336-345
26. M. Lipsitch J.K. Dykes S.E. Johnson E.W. Ades J. King D.E. Briles G.M. Carlone Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model Vaccine 8 2000 2895-2901
27. M. Lipsitch Interpreting results from trials of pneumococcal conjugate vaccines a statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes Am J Epidemiol 154 2001 85-92
28. P. Calverley R. Pauwels J. Vestbo P. Jones N. Pride A. Gulsvik J. Anderson C. Maden Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial Lancet 361 2003 449-456
29. R.B. Dowling M. Johnson P.J. Cole R. Wilson Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro Eur Respir J 14 1999 363-369
30. S. Jonsson G. Vidarsson H. Valdimarsson G. Schiffman R. Schneerson I. Jonsdottir Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine Eur Respir J 20 2002 813-818
31. J. Eller A. Ede T. Schaberg M.S. Niederman H. Mauch H. Lode Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function Chest 113 1998 1542-1548
32. M. Miravitlles C. Espinosa E. Fernández-Laso J.A. Martos J.A. Maldonado M. Gallego Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD Chest 116 1999 40-46
33. C. Cornu D. Yzebe P. Leophonte J. Gaillat J.P. Boissel M. Cucherat Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: A meta-analysis of randomized trials Vaccine 19 2001 4780-4790
34. M.R. Jacobs D. Felmingham P.C. Appelbaum R.N. Gruneberg The Alexander Project 1998-2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents J Antimicrob Chemother 52 2003 229-246
35. G.W. Amsden I.M. Baird S. Simon G. Treadway Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis Chest 123 2003 772-777
36. A.A. Firsov S.H. Zinner S.N. Vostrov O.V. Kononenko Y.A. Portnoy L.V. Shustova I.B. Kadenatsi Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils J Antimicrob Chemother 49 2002 113-119
37. K.A. Rodvold L.H. Danziger M.H. Gotfried Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults Antimicrob Agents Chemother 47 2003 2450-2457
38. Y. le Normand H. Drugeon S. Abbas B. Palestro Une modelisation informatique pour une meilleure comprehension de la relation PK/PD: application a l'azithromycine dans le traitement de l'angine aigue streptococcique et des exacerbations aigues de la bronchite chronique Therapie 59 2004 155-162
39. G.W. Amsden A.N. Nafziger G. Foulds Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1500 milligrams, given over a 3- or 5-day period in healthy subjects Antimicrob Agents Chemother 43 1999 163-165
40. G.W. Amsden Pneumococcal macrolide resistance-myth or reality? J Antimicrob Chemother 44 1999 1-6